Company Filing History:
3 out of 8 
3 out of 6 
1 out of 2 Years Active: 2004-2019
Title: Ludger Ständker: A Pioneer in Antagonistic Peptide Research
Introduction
Ludger Ständker is a notable inventor based in Hannover, Germany, recognized for his contributions to biomedical research, particularly in the field of peptide-based therapeutics. With an impressive portfolio of 9 patents to his name, Ständker has made significant strides in developing innovative solutions to combat various health challenges, including viral infections.
Latest Patents
Among his latest patents, one highlights the development of peptides with antagonistic activities against the natural CXCR4 receptor. This innovative peptide has proven effective in blocking the CXC-chemokine receptor 4 (CXCR4) mediated HIV-1 NL4-3 infection, demonstrating an IC value of less than 50 μM, which suggests strong potential for therapeutic use. Another noteworthy patent involves a process for preparing human relaxin-2, specifically focusing on a proprietary amino acid sequence that enhances its therapeutic applicability.
Career Highlights
Throughout his career, Ludger Ständker has partnered with notable companies such as Pharis Biotec GmbH and Ipf Pharmaceuticals GmbH, where he has played a critical role in the advancement of peptide research. His work has contributed significantly to the understanding and potential treatment of viral infections, showcasing his dedication to innovation in the biomedical field.
Collaborations
Ständker's collaborative efforts with esteemed researchers such as Wolf-Georg Forssmann and Frank Kirchhoff have further enhanced his impact in the scientific community. These partnerships have fostered a conducive environment for innovation and have led to groundbreaking research developments.
Conclusion
Ludger Ständker stands out as a leading inventor whose work in the field of peptide therapeutics continues to pave the way for novel treatments. His contributions not only reflect his expertise as an inventor but also underline the importance of collaboration in achieving meaningful advancements in biomedical research.